BBNX vs SENS
BBNX: Beta Bionics is a medical technology company developing automated insulin delivery systems to simplify diabetes management and improve patient outcomes. SENS: Senseonics develops implantable continuous glucose monitoring systems that stay under the skin for up to one year, offering diabetes patients longer intervals between sensor replacements than conventional CGM devices.
Side-by-side fundamentals
| Metric | BBNX | SENS | Edge |
|---|---|---|---|
| Price as of 2026-08-07 close | $15.90 | $7.02 | |
| Market cap as of 2026-08-10 | $715M | $371M | |
| PEG as of 2026-08-10 | n/a | -0.20 | |
| Net margin as of 2026-08-10 | -61.3% | -214.2% | BBNX higher |
| Gross margin as of 2026-08-10 | +58.3% | +52.1% | BBNX higher |
| Operating margin as of 2026-08-10 | -69.8% | -212.9% | BBNX higher |
| ROE as of 2026-08-10 | -26.3% | -130.0% | BBNX higher |
| ROA as of 2026-08-10 | -23.3% | -67.2% | BBNX higher |
| Debt / equity as of 2026-08-10 | 0.00 | 1.05 | BBNX lower |
| Revenue growth (YoY) as of 2026-08-10 | +94.1% | +71.9% | BBNX higher |
| Revenue CAGR (3y) SEC XBRL | +189.1% | +29.1% | BBNX higher |
| Beta as of 2026-08-10 | 0.61 | 1.01 | |
| 1-year return as of 2026-08-07 close | +5.4% | -24.2% | BBNX higher |
Fundamentals: market data, as of 2026-08-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-07.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.